Researchers designed a new nanoparticle adjuvant that may be more potent than others now in use. Studies in mice showed it significantly improved antibody production following vaccination against HIV, diphtheria and influenza.
Researchers designed a new nanoparticle adjuvant that may be more potent than others now in use. Studies in mice showed it significantly improved antibody production following vaccination against HIV, diphtheria and influenza.